Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

The clinical efficacy of current therapies for Hepatocellular carcinoma (HCC) are unsatisfactory. In recent years, chimeric antigen receptor (CAR) T-cell therapies have been developed for solid tumors including advanced HCC (aHCC), but limited progress has been made. Glypican-3 is a promising immuno...

Full description

Bibliographic Details
Main Authors: Hongwei Sun, Chongyun Xing, Songfu Jiang, Kang Yu, Shengjie Dai, Hongru Kong, Yuepeng Jin, Yunfeng Shan, Wenjun Yang, Zhen Wang, Jun Xiao, Huamao Wang, Wei Wang, Zonghai Li, Keqing Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T cell therapy
liver cancer
hepatocellular carcinoma
glypican-3
sorafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.963031/full

Similar Items